No Data
No Data
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx-Melanoma Test, Contributing to Personalized Management of Patients With Melanoma
Here's Why Agios Stock Plummeted More Than 20% on Monday
Insider Sale: Director at $CSTL (CSTL) Sells 4,669 Shares
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
JANX Stock Hits Record High on Prostate Cancer Study Data